[{"address1": "1400 Sierra Point Parkway", "address2": "Building C Suite 200", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 822 5500", "fax": "650 636 9773", "website": "https://www.annexonbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barr\u00e9 syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.", "fullTimeEmployees": 70, "auditRisk": 3, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 5.2, "open": 5.25, "dayLow": 4.93, "dayHigh": 5.3, "regularMarketPreviousClose": 5.2, "regularMarketOpen": 5.25, "regularMarketDayLow": 4.93, "regularMarketDayHigh": 5.3, "beta": 1.297, "forwardPE": -4.7428575, "volume": 2550464, "regularMarketVolume": 2550464, "averageVolume": 2895559, "averageVolume10days": 2246890, "averageDailyVolume10Day": 2246890, "bid": 4.96, "ask": 5.01, "bidSize": 500, "askSize": 500, "marketCap": 524961728, "fiftyTwoWeekLow": 1.57, "fiftyTwoWeekHigh": 8.4, "fiftyDayAverage": 5.0317, "twoHundredDayAverage": 4.09015, "currency": "USD", "enterpriseValue": 226053072, "floatShares": 67044610, "sharesOutstanding": 105414000, "sharesShort": 7569377, "sharesShortPriorMonth": 4142098, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.08189999, "heldPercentInsiders": 0.0039500003, "heldPercentInstitutions": 0.95533997, "shortRatio": 4.1, "shortPercentOfFloat": 0.1009, "impliedSharesOutstanding": 105414000, "bookValue": 2.9, "priceToBook": 1.7172413, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -120737000, "trailingEps": -1.46, "forwardEps": -1.05, "pegRatio": -0.14, "enterpriseToEbitda": -1.754, "52WeekChange": 0.4887892, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ANNX", "underlyingSymbol": "ANNX", "shortName": "Annexon, Inc.", "longName": "Annexon, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "39e86d0b-392a-371c-9e14-996bb9ee6158", "messageBoardId": "finmb_279883519", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.98, "targetHighPrice": 30.0, "targetLowPrice": 10.0, "targetMeanPrice": 16.4, "targetMedianPrice": 14.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 264948000, "totalCashPerShare": 2.867, "ebitda": -128903000, "totalDebt": 30785000, "quickRatio": 20.174, "currentRatio": 20.615, "debtToEquity": 11.732, "returnOnAssets": -0.28597, "returnOnEquity": -0.50595003, "freeCashflow": -73527128, "operatingCashflow": -116416000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]